Calcium dobesilate reduces VEGF signaling by interfering with heparan sulfate binding site and protects from vascular complications in diabetic mice
Fig 7
Effect of CaD treatment on diabetic complications in vivo.
Type I diabetes was induced in Sv129 mice and thereafter the diabetic mice were daily treated with vehicle or CaD (100mg/kg) or enalapril (30mg/kg). CaD treatment had no effect on hyperglycemia (A and B) and body weight (C). CaD treatment protects kidney function in diabetic mice as reflected by serum creatinine levels (D) and albuminuria (E). CaD treatment reduces diabetic neuropathy as reflected by sensory nerve conduction velocity measurements (F). The results are expressed as the mean+SEM (n = 20 mice for each group). *p<0.05, **p<0.01 and ***p<0.001 versus vehicle treated diabetic mice (STZ).